Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MTP-101LF
- Development stage
- Phase 2
- Lead developer
- University of Minnesota
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Colonoscopy, Sigmoidoscopy, Enema
01
Overview
MTP-101LF is a fecal microbiota transplantation (FMT) product being evaluated for the treatment of chronic granulomatous disease (CGD)-associated colitis. CGD is a primary immunodeficiency that often leads to inflammatory bowel disease-like symptoms due to impaired neutrophil function and subsequent gut dysbiosis. MTP-101LF consists of a healthy-donor microbiome preparation intended to restore microbial diversity and balance in the recipient's colon, thereby reducing inflammation. The product is administered via colonoscopy and is currently being evaluated in a pilot study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).
- Other names
- fecal microbiota transplantationFMT
Beyond the preview
Go deeper on MTP-101LF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MTP-101LF.